Description of the Characteristics of Multiple Sclerosis Patients in the Region of Valencia (Spain) Who Requested Treatment with Disease-Modifying Drugs during the 2005-2014 Decade

Publisher： Karger

E-ISSN： 1421-9913|75|5-6|274-281

ISSN： 0014-3022

Source： European Neurology, Vol.75, Iss.5-6, 2016-06, pp. : 274-281

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate

By  

European Neurology, Vol. 65, Iss. 4, 2011-03 ,pp. : 231-232

Karger

Access to resources Recommend Favorite

Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs

By Tan Jing  

Clinical Rheumatology, Vol. 31, Iss. 8, 2012-08 ,pp. : 1169-1175

Springer Publishing Company

Access to resources Recommend Favorite

Adherence to Disease-Modifying Therapies in Spanish Patients with Relapsing Multiple Sclerosis: Two-Year Interim Results of the Global Adherence Project

By  

European Neurology, Vol. 65, Iss. 2, 2011-01 ,pp. : 59-67

Karger

Access to resources Recommend Favorite

Efficacy of Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis: A Systematic Comparison

By  

European Neurology, Vol. 60, Iss. 1, 2008-04 ,pp. : 1-11

Karger

Access to resources Recommend Favorite

A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology

By Takamura Akito  

Modern Rheumatology, Vol. 23, Iss. 2, 2013-03 ,pp. : 297-303

Springer Publishing Company

Access to resources Recommend Favorite